AR052429A1 - Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo - Google Patents
Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararloInfo
- Publication number
- AR052429A1 AR052429A1 ARP050105412A ARP050105412A AR052429A1 AR 052429 A1 AR052429 A1 AR 052429A1 AR P050105412 A ARP050105412 A AR P050105412A AR P050105412 A ARP050105412 A AR P050105412A AR 052429 A1 AR052429 A1 AR 052429A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- independently selected
- preparation
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuesto de arilpiridina de formula (1) en la que X es N y Y es CH, o X es CH y Y es N; Z es O, S, SO o SO2; R1 es CO2H, CONHSO2R6, CH2CO2H, NR4COR7, tetrazol o CH2tetrazol; R2a y R2b se seleccionan cada uno independientemente entre H, halo, CN, SO2alquilo, SR5, NO2, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R3a y R3b se seleccionan cada uno independientemente entre H, halo, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido o NR10R11; Rx es alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, CQaQb opcionalmente sustituido-heterociclilo, CQaQb opcionalmente sustituido- heterociclilo bicíclico o CQaQb opcionalmente sustituido-arilo; R4 es H o un alquilo opcionalmente sustituido; R5 es H o un alquilo opcionalmente sustituido; R6 es alquilo opcionalmente sustituido, arilo opcionalmente sustituido o heterociclilo opcionalmente sustituido; R7 es alquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilo opcionalmente sustituido, alcoxi opcionalmente sustituido, heterocicliloxi opcionalmente sustituido o ariloxi opcionalmente sustituido; R8 es H, F, o alquilo; R9 es H, hidroxi, F o alquilo; o R8 y R9, junto con el átomo de C al que están unidos, forman un anillo cicloalquilo que opcionalmente contiene hasta un heteroátomo seleccionado entre O, S, NH y N- alquilo; o R8 y R9 junto con el C al que están unidos forman un grupo carbonilo; Qa y Qb se seleccionan cada uno independientemente entre H, CH3 y F; R10 y R11 se seleccionan cada uno independientemente entre H o alquilo; o R10 y R11, junto con el N al que están unidos forman un anillo heterocíclico alifático que opcionalmente contiene un heteroátomo adicional seleccionado entre O, S, NH y N- alquilo; y sus derivados. Composicion farmacéutica que lo comprende y su uso para la elaboracion de un medicamento para el tratamiento de dolor inflamatorio, neuropático visceral, trastorno inflamatorio, inmunologico, oseo, neurodegenerativo o renal. Procedimiento para la preparacion de dicho compuesto de formula (1).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0428263A GB0428263D0 (en) | 2004-12-23 | 2004-12-23 | Compounds |
| GB0508458A GB0508458D0 (en) | 2005-04-26 | 2005-04-26 | Compounds |
| GB0524675A GB0524675D0 (en) | 2005-12-02 | 2005-12-02 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052429A1 true AR052429A1 (es) | 2007-03-21 |
Family
ID=35735391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105412A AR052429A1 (es) | 2004-12-23 | 2005-12-21 | Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100137378A1 (es) |
| EP (2) | EP2053042A1 (es) |
| JP (1) | JP2008525363A (es) |
| KR (1) | KR20070091301A (es) |
| AR (1) | AR052429A1 (es) |
| AT (1) | ATE424386T1 (es) |
| AU (1) | AU2005318372A1 (es) |
| BR (1) | BRPI0519398A2 (es) |
| CA (1) | CA2592442A1 (es) |
| DE (1) | DE602005013116D1 (es) |
| EA (2) | EA200801909A1 (es) |
| ES (1) | ES2321535T3 (es) |
| IL (1) | IL183781A0 (es) |
| MA (1) | MA29082B1 (es) |
| MX (1) | MX2007007830A (es) |
| NO (1) | NO20073332L (es) |
| PE (2) | PE20060838A1 (es) |
| TW (1) | TW200640865A (es) |
| UY (1) | UY29298A1 (es) |
| WO (1) | WO2006066968A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0608825D0 (en) * | 2006-05-04 | 2006-06-14 | Glaxo Group Ltd | Compounds |
| EP2158183A2 (en) * | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| FR2921062A1 (fr) | 2007-09-17 | 2009-03-20 | Commissariat Energie Atomique | Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications |
| EP2421835A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
| CN102596199A (zh) | 2009-07-31 | 2012-07-18 | 潘米拉制药公司 | Dp2受体拮抗剂的眼用医药组合物 |
| CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
| EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
| MA40281B1 (fr) | 2014-06-03 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
| RU2020134082A (ru) | 2014-10-06 | 2020-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы регулятора трансмембранной проводимости при муковисцидозе |
| PL3436446T3 (pl) | 2016-03-31 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
| SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| DK3551622T3 (da) | 2016-12-09 | 2020-11-23 | Vertex Pharma | Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren |
| CN110072521B (zh) | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
| US10899695B2 (en) | 2017-02-06 | 2021-01-26 | Idorsia Pharmaceuticals Ltd | Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AR112467A1 (es) | 2017-08-02 | 2019-10-30 | Vertex Pharma | Procesos para preparar compuestos |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1471276A (en) | 1975-01-22 | 1977-04-21 | Nippon Shinyaku Co Ltd | 5-benzylpicolinic acid deri vatives |
| EP0388682A1 (de) | 1989-03-15 | 1990-09-26 | Bayer Ag | Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| JPH09507846A (ja) | 1993-12-30 | 1997-08-12 | スミスクライン・ビーチャム・コーポレイション | フェニルメチルヘキサンアミドおよびその使用 |
| GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| GB9420557D0 (en) * | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
| AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| CN1107058C (zh) | 1995-02-13 | 2003-04-30 | G·D·瑟尔公司 | 用于治疗类症的取代的异噁唑 |
| TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
| TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
| DE69635254T2 (de) | 1995-07-07 | 2006-07-13 | Astrazeneca Ab | Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| EP0892791B1 (en) | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
| SI0912518T1 (en) | 1996-07-18 | 2003-12-31 | Merck Frosst Canada & Co. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| ES2231757T3 (es) | 1997-09-05 | 2005-05-16 | Glaxo Group Limited | Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina. |
| US6362009B1 (en) * | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| WO1999041237A1 (en) | 1998-02-13 | 1999-08-19 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
| JP3420751B2 (ja) | 1998-11-03 | 2003-06-30 | グラクソ グループ リミテッド | 選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体 |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
| ATE261444T1 (de) | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
| EP1216238B1 (en) | 1999-09-14 | 2004-02-18 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| AU2003216920A1 (en) | 2002-04-08 | 2003-10-20 | Glaxo Group Limited | (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives |
| GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| MXPA05004715A (es) | 2002-10-30 | 2005-08-03 | Merck Frosst Canada Inc | Derivados de piridopirrolizina y piridoindolizina. |
| GB0225548D0 (en) * | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
| GB0306329D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Compounds |
| GB0323585D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
| GB0323584D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
| GB0323581D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Novel compounds |
| DE602004011966T2 (de) | 2003-10-24 | 2009-02-12 | Glaxo Group Ltd., Greenford | Heterocyclylverbindungen |
| GB0328024D0 (en) | 2003-12-03 | 2004-01-07 | Glaxo Group Ltd | Compounds |
| GB0410121D0 (en) | 2004-05-06 | 2004-06-09 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-12-21 WO PCT/EP2005/014061 patent/WO2006066968A1/en active Application Filing
- 2005-12-21 EA EA200801909A patent/EA200801909A1/ru unknown
- 2005-12-21 AR ARP050105412A patent/AR052429A1/es unknown
- 2005-12-21 US US11/722,402 patent/US20100137378A1/en not_active Abandoned
- 2005-12-21 JP JP2007547393A patent/JP2008525363A/ja not_active Withdrawn
- 2005-12-21 AU AU2005318372A patent/AU2005318372A1/en not_active Abandoned
- 2005-12-21 AT AT05817767T patent/ATE424386T1/de not_active IP Right Cessation
- 2005-12-21 EP EP09150218A patent/EP2053042A1/en not_active Withdrawn
- 2005-12-21 DE DE602005013116T patent/DE602005013116D1/de active Active
- 2005-12-21 UY UY29298A patent/UY29298A1/es unknown
- 2005-12-21 CA CA002592442A patent/CA2592442A1/en not_active Abandoned
- 2005-12-21 KR KR1020077014271A patent/KR20070091301A/ko not_active Application Discontinuation
- 2005-12-21 ES ES05817767T patent/ES2321535T3/es active Active
- 2005-12-21 EP EP05817767A patent/EP1833795B1/en active Active
- 2005-12-21 BR BRPI0519398-2A patent/BRPI0519398A2/pt not_active IP Right Cessation
- 2005-12-21 EA EA200701324A patent/EA200701324A1/ru unknown
- 2005-12-21 MX MX2007007830A patent/MX2007007830A/es not_active Application Discontinuation
- 2005-12-21 TW TW094145424A patent/TW200640865A/zh unknown
-
2006
- 2006-01-03 PE PE2006000025A patent/PE20060838A1/es not_active Application Discontinuation
- 2006-01-30 PE PE2008001431A patent/PE20081440A1/es not_active Application Discontinuation
-
2007
- 2007-06-06 MA MA29966A patent/MA29082B1/fr unknown
- 2007-06-07 IL IL183781A patent/IL183781A0/en unknown
- 2007-06-21 US US11/766,418 patent/US7759369B2/en not_active Expired - Fee Related
- 2007-06-28 NO NO20073332A patent/NO20073332L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100137378A1 (en) | 2010-06-03 |
| EP2053042A1 (en) | 2009-04-29 |
| PE20060838A1 (es) | 2006-10-12 |
| ATE424386T1 (de) | 2009-03-15 |
| MX2007007830A (es) | 2007-07-25 |
| US20080249138A1 (en) | 2008-10-09 |
| ES2321535T3 (es) | 2009-06-08 |
| EP1833795A1 (en) | 2007-09-19 |
| EA200701324A1 (ru) | 2007-10-26 |
| NO20073332L (no) | 2007-09-17 |
| MA29082B1 (fr) | 2007-12-03 |
| IL183781A0 (en) | 2007-09-20 |
| WO2006066968A1 (en) | 2006-06-29 |
| DE602005013116D1 (de) | 2009-04-16 |
| UY29298A1 (es) | 2006-05-31 |
| US7759369B2 (en) | 2010-07-20 |
| JP2008525363A (ja) | 2008-07-17 |
| AU2005318372A1 (en) | 2006-06-29 |
| BRPI0519398A2 (pt) | 2009-01-20 |
| PE20081440A1 (es) | 2008-12-31 |
| EA200801909A1 (ru) | 2009-06-30 |
| EP1833795B1 (en) | 2009-03-04 |
| KR20070091301A (ko) | 2007-09-10 |
| TW200640865A (en) | 2006-12-01 |
| CA2592442A1 (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052429A1 (es) | Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo | |
| HRP20161786T1 (hr) | Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze | |
| AR034261A1 (es) | Compuestos derivados de pirazol[1,5-a]piridina; composiciones farmaceuticas, su uso en la fabricacion de medicamentos, y metodos de tratamiento de enfermedades mediadas por quinasas | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR107154A1 (es) | Estimuladores de guanilato ciclasa soluble | |
| AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| ECSP12011867A (es) | Derivados bencimidazol-imidazol | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| AR048834A1 (es) | Compuestos derivados de piperidina o tropano; metodos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por quimioquinas (ccr5) | |
| AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
| AR076117A1 (es) | Derivados de pirimidin -4- ilpropanodinitrilo, procedimiento para su preparacion, asi como su utilizacion en calidad de herbicidas y agentes reguladores del crecimiento de las plantas | |
| AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| AR041066A1 (es) | 2,5-dioxoimidazolidin-4-il-acetamidas y analogos como inhibidores de la metaloproteinasa mmp12 | |
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| AR037996A1 (es) | Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento | |
| IL272762B2 (en) | Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases | |
| TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR041875A1 (es) | Compuesto de fenilo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento y procedimiento para preparar dicho compuesto | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |